SWEDISH ORPHAN BIOVITRUM

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2010-01-01

Employees: -

Market Cap: $10.7B

Website: http://www.sobi.com/

Clinical Trials

A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant

Terminated

Conditions: Graft Failure

Interventions: Procedure: blood collection

First Posted Date: 2020-07-31

Last Posted Date: 2022-10-21

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 101

Registration Number: NCT04494061

Locations: 🇧🇪
Algemeen Ziekenhuis Delta - Campus Rumbeke, Roeselare, West-Vlaanderen, Belgium
🇫🇷
Hôpital Pontchaillou, Rennes cedex 9, Bretagne, France
🇫🇷
Centre Hospitalier Universitaire Estaing, Clermont-Ferrand, Rhône, France

and more 22 locations

Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.

Phase 2

Terminated

Conditions: SARS-CoV-2

Interventions: Biological: Anakinra
Biological: Emapalumab

First Posted Date: 2020-03-27

Last Posted Date: 2022-03-10

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 16

Registration Number: NCT04324021

Locations: 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Regions hospital, Saint Paul, Minnesota, United States
🇺🇸
The Valley hospital, Ridgewood, New Jersey, United States

and more 9 locations

A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health

Active, not recruiting

Conditions: Hemophilia A

Interventions: Drug: ELOCTA

First Posted Date: 2020-03-03

Last Posted Date: 2024-10-03

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 427

Registration Number: NCT04293523

Locations: 🇫🇮
Helsinki University Central Hospital, New Children Hospital, Helsinki, Finland
🇫🇮
Turku University Central Hospital, Paediatric and adolescent haematology and oncology clinic, Turku, Finland
🇬🇷
Ippokrateio Hospital Thessaloniki (pediatric department), Thessaloníki, Greece

and more 49 locations

Impact on French Physician's Haemophilia Treatment Management Decision Based on Systematic Joint Examination

Not Applicable

Completed

Conditions: Hemophilia A

Interventions: Procedure: Ultrasound, Haemophilia Joint Health Score

First Posted Date: 2019-10-21

Last Posted Date: 2024-07-03

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 88

Registration Number: NCT04133883

Locations: 🇫🇷
Swedish Orphan Biovitrum Reserach site, Paris, France
🇫🇷
Swedish Orphan Biovitrum Research Site, Tours, France
🇫🇷
Swedish Orphan Biovitrum Research site, Toulouse, France

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH

Phase 2

Terminated

Conditions: Hemophagocytic Lymphohistiocytoses

Interventions: Drug: Emapalumab-Lzsg

First Posted Date: 2019-06-13

Last Posted Date: 2023-10-06

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 7

Registration Number: NCT03985423

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A

Completed

Conditions: Hemophilia A With Inhibitor

Interventions: Other: rFVIIIFc

First Posted Date: 2019-05-15

Last Posted Date: 2024-07-03

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 44

Registration Number: NCT03951103

Locations: 🇨🇭
Swedish Orphan Biovitrum Research Site, Bern, Switzerland
🇸🇦
Swedish Orphan Biovitrum Research Site (a), Riyadh, Saudi Arabia
🇸🇦
Swedish Orphan Biovitrum Research Site (p), Riyadh, Saudi Arabia

Long-term Safety Study of Kineret® in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)

Completed

Conditions: Still Disease, Juvenile Onset

Interventions: Drug: Anakinra

First Posted Date: 2019-04-30

Last Posted Date: 2019-11-14

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 306

Registration Number: NCT03932344

Locations: 🇮🇹
IRCCS Istituto G. Gaslini, Genova, Italy

An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B

Active, not recruiting

Conditions: Hemophilia B

Interventions: Drug: Alprolix

First Posted Date: 2019-04-03

Last Posted Date: 2024-07-03

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 151

Registration Number: NCT03901755

Locations: 🇬🇧
Swedish Orphan Biovitrum Research Site, Oxford, United Kingdom
🇬🇷
Swedish Orphan Biovitrum Research Site (Haemophilia Center Aghia Sophia Children's Hospital), Athens, Greece
🇸🇦
Swedish Orphan Biovitrum Research Site (King Faisal Hospital pediatric), Riyadh, Saudi Arabia

and more 6 locations

A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients

Phase 1

Completed

Conditions: Sanfilippo Syndrome Type A (MPS IIIA)

Interventions: Drug: SOBI003

First Posted Date: 2019-01-22

Last Posted Date: 2022-02-25

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 6

Registration Number: NCT03811028

Locations: 🇺🇸
Children´s Hospital and research center, Oakland, California, United States
🇹🇷
Gazi University Hospital, Ankara, Turkey
🇺🇸
University of North Carolina hospitals, Chapel Hill, North Carolina, United States

A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France

Completed

Conditions: Haemophilia B

Interventions: Drug: Alprolix

First Posted Date: 2018-08-31

Last Posted Date: 2024-07-03

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 91

Registration Number: NCT03655340

Locations: 🇫🇷
Swedish Orphan Biovitrum Research Site, Toulouse, France
🇫🇷
Swedish Orphan Biovitrum Research Site (CHU de Bordeaux), Bordeaux, France
🇫🇷
Swedish Orphan Biovitrum research site, Strasbourg, France

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy